Phase 3 results show substantial weight loss with retatrutide, but it remains experimental. Experts caution against buying unapproved versions online.
Retatrutide has produced striking weight loss in clinical trials, but it’s still an experimental medicine. The latest reported results found that participants taking the highest dose lost an average of 28.7% of their body weight over 68 weeks. That makes the drug an important one to watch, especially for people who haven’t responded to existing treatments. It doesn’t establish that retatrutide is safe or suitable for routine use, though—and versions offered online may not contain a reliably made product.
The medicine, developed by Eli Lilly, is in phase 3 clinical trials. Trial results have not yet been submitted for review for approval, and there’s no set timeline for when it could become available for routine prescribing. For now, access is through clinical trials. The gap between promising trial findings and established treatment is why specialists advise against seeking out online products.
What the trial results show
Retatrutide is given as a once-weekly injection. Like semaglutide, sold as Wegovy and Ozempic, and tirzepatide, sold as Zepbound, it can reduce appetite and slow digestion. Its distinguishing feature is that it acts on three hormone receptors: GLP-1, GIP and glucagon. Semaglutide acts on GLP-1 receptors, while tirzepatide acts on GLP-1 and GIP receptors.
The idea behind targeting three receptors is that the combined effects might produce greater weight loss. Mir Ali, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in California, describes retatrutide as the first medicine in development to act on all three. That mechanism offers a reason to study it, but it doesn’t by itself show how well the medicine works or how its risks compare with other treatments.
In the reported phase 3 results, participants taking the highest dose lost an average of 28.7% of their body weight over 68 weeks. For context, trials of tirzepatide reported average losses of 15% to 22.5% over 72 weeks; trials of semaglutide reported average losses of 10% to 15% over 68 weeks. These are results from separate trials, so they aren’t a direct head-to-head comparison. Differences between studies can affect how results line up.
Some participants reportedly left retatrutide trials because they felt they had lost too much weight. That detail signals why researchers need to assess not just how much weight people lose, but also how they feel, what side effects occur and whether the benefits and harms remain acceptable over time. Trial findings are a useful early measure of potential, not a guarantee that any individual will have the same result.
Why online versions raise concerns
Despite its experimental status, retatrutide has been offered for sale online. The source article reports that a public safety notice issued in early February said retatrutide and another experimental medicine, cagrilintide, cannot be used in compounded products. The notice also said neither substance is an ingredient in an approved medicine or has been established as safe and effective for a health condition.
Compounding pharmacies can prepare customized medicines in some circumstances, including when approved products are in short supply. But a compounded product may not be made under the same level of oversight as an approved medicine. Richard Siegel, codirector of the Diabetes and Lipid Center at Tufts Medical Center, warns that the ingredients or concentration in a compounded product may differ from what it is meant to imitate. That can make its effects less predictable.
Ali cautions that buying directly from a compounding pharmacy can leave a person with a product that is unsafe or ineffective. Siegel says that medicines are reviewed for potential harms, including side effects that may emerge during use. With an experimental product sold outside a clinical trial, patients may have less information about what they are receiving and what risks to expect. When a treatment is available in an approved form, Ali says, its effects and side effects are better studied.
Price or frustration with a current medication can make an online offer tempting, particularly for someone who hasn’t lost as much weight as hoped. But retatrutide’s reported trial results don’t confirm that an online version is authentic, correctly prepared or appropriate for a particular person. The clinical evidence applies to the medicine studied in trials, not automatically to products bought from other sources.
What to consider if treatment isn’t working
People who haven’t responded well to one weight management medicine have other options to discuss with a clinician. Siegel suggests talking with a health care provider about another medicine or strategy. If primary care hasn’t helped identify a suitable next step, Ali suggests seeking a specialist in obesity medicine, who may be more familiar with available treatments.
Weight management care can involve more than medication. Siegel describes a broader plan that includes self-monitoring, nutrition and physical activity, with both aerobic and resistance exercise. A clinician can help tailor these elements to a person’s health and circumstances. The trial results alone don’t show what combination of treatment will be right for any one patient.
People considering medication, or concerned that an existing treatment isn’t helping, can bring those questions to a health care provider with experience in weight management. Ali notes that these medicines are intended for people with significant weight to lose and may be used long term. That makes careful review of a treatment’s evidence and source especially relevant. Retatrutide’s results warrant attention, but its current status is still experimental.
